The Latest
-
Stock via Getty Images
Q&ALilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics
The pharma giant’s R&D in Alzheimer’s didn’t end with last year’s Kisunla approval, and diagnostics could define where the company goes next.
-
stock via Getty Images
With DTC ads under fire, pharma companies need to pivot
An executive order from HHS doesn’t prohibit direct outreach to consumers, but drugmakers will need to rethink their outreach strategies.
-
Stock via Getty Images
3 FDA approval firsts that could be around the corner
Several market-altering decisions are on the agency’s docket for the rest of 2025.
-
Stock via Getty Images
How pharma can play a role in the $1 trillion healthcare reinvention
A report from PwC takes a long-term approach to the shifts in healthcare and finds that efficiency in R&D and adaptable business models will define the drugmaker of the future.
-
Stock via Getty Images
AI agents are coming to pharma. Here’s what it means for clinical trials.
The high-tech helpers could autonomously navigate tedious tasks — but have to be carefully implemented.
-
Stock via Getty Images
Biotech’s VC slowdown forces young drugmakers to adapt in the ‘valley of death’
Amid the sector’s long winter, startups are shifting gears to extend their cash runways.
-
Permission granted by Takeda
From atop Mt. Fuji, a Takeda team heralds a need for human plasma
The climb aimed to raise money and awareness as Takeda ramps up its plasma-derived therapy presence in Japan.
-
Sean Gallup via Getty Images
Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?
While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.
-
Stock via Getty Images
4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next
The company scored the first-ever approval to treat a potentially deadly infection leveraging its gene therapy platform.
-
aprott via Getty Images
Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.
Growing research suggests various ways weight loss drugs could have an impact in cancer care.
-
Dragos Condrea via Getty Images
A new class of sleep drugs draws Wall Street’s attention
Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.
-
Stock via Getty Images
Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.
While the EU and UK attempt to lure scientists with new financial incentives, Basel’s stable economy and emphasis on science remains a draw.
-
Stock via Getty Images
Inside pharma’s race to deliver new treatments for dwarfism
By targeting the underlying genetic mutation that drives the condition, researchers hope to increase height and address debilitating complications.
-
Stock via Getty Images
Q&ACan new Alzheimer’s tests help clear the way for the next generation of therapies?
A tau-related blood test could offer more insight in early-disease pathology to the complicated Alzheimer’s disease space.
-
Andrew Harnik via Getty Images
At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves
Robert F. Kennedy Jr. faced criticism Thursday even from Republican lawmakers over changes to federal vaccine policy as well as a leadership crisis at the CDC.
-
Stock via Getty Images
International appeal: Europe and UK lure US scientists with financial incentives
With slashed budgets and decimated research programs, American scientists are increasingly looking for career opportunities abroad.
-
Sergey Balakhnichev via Getty Images
Why drugmakers may need to borrow from quantum theory to confront tariff and pricing threats
With so many unknowns surrounding regulatory and policy shifts, pharma companies might need to consider fundamental changes to how they operate, a Deloitte analyst said.
-
Stock via Getty Images
How AI advances will shape the drugmaker of the future
An AI revolution is taking place, and leaders from tech to Big Pharma are forecasting what drugmakers of the future will look like.
-
Joe Raedle via Getty Images
FDA approves updated COVID boosters, but narrows use
In a post on X, HHS Secretary Robert F. Kennedy said the FDA has cleared vaccines from Pfizer, Moderna and Novavax for use in "high risk" individuals.
Updated Aug. 27, 2025 -
Eva Marie Uzcategui via Getty Images
How a SpaceX mission could speed drug discoveries on Earth
Research enabled by blasting off into space could lead to better treatments for diseases such as ALS and Parkinson’s.
-
Stock via Getty Images
A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant
Newcomers looking for a way into the obesity space are developing unique methods to snag market share.
-
Stock via Getty Images
AbbVie dives back into the neuro pool with a $1.2B psychedelics play
Following a major clinical failure last year, AbbVie’s purchase of a psychedelic depression treatment has the potential to revive a touch-and-go market.
-
Sarah Silbiger via Getty Images
Why an FDA decision for a new drug could ripple through the ultra-rare disease space
All eyes are on Stealth BioTherapeutics as it awaits a long-delayed approval for its first-in-class treatment for Barth syndrome.
-
Anna Moneymaker via Getty Images
FDA’s new accelerated pathway could open pharma up to risks, as well as benefits
Faster review times will leave drugmakers vulnerable to litigation, while new Trump administration priorities add more uncertainty in the drug approval process.
-
Justin Sullivan via Getty Images
And just like that... pharma’s breakups reveal pain points in cancer R&D
Biotech tie-ups with Gilead, Genetech and Ipsen that have recently been let go.
